DLL4/NOTCH1/PPARγ agonists and/or PI3K/AKT antagonists are attractive therapeutic targets for preventing or even possibly reversing progressive pathologic vasculopathy in PAH. The gene discussed is DLL4; the disease is pulmonary arterial hypertension.